Visionary pioneers, Biosceptre’s researchers are leading the way with the development of our multi-targeted BRiDGECAR™ system, including our nfP2X7-targeted technology, that has the potential to benefit millions of cancer patients across the world.

Headquartered in the UK, Biosceptre is undertaking therapeutic development efforts in Sydney, Australia and has secured a significant global IP portfolio.

With Nobel prize-winning science leadership, globally-renowned researchers and collaboration with major research institutes, Biosceptre is committed to a future of multi-targeted oncology therapeutics, where nfP2X7 technology forms the cornerstone.


We’re not alone…

We are supported by the ongoing partnerships with global experts and major research institutes that expand our science and augment our therapeutic pipeline.

Our therapies have the potential to generate equity value measured in the billions and to deliver real improvement for millions of people.


The results from our studies are promising. Our primary focus is on rapidly delivering our BRiDGECAR™ therapies to cancer patients that are not well served by current treatment options. Alongside this, we will continue to expand our pipeline, including the development of targeted antibody therapeutics, with the aim of delivering a range of products capable of rapid scaling to meet potential global demand.


Advances in technology need vision and support. An investment in our technology is a commitment beyond cancer – to better outcomes and improved lives for millions of cancer patients across the world.


Go to Top